PriceTargets.com logo

Oncology Institute - TOI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 1,288.89%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.18 As of 11/15/2024 01:00 AM ET
▼ -0.06 (-25.00%)

This chart shows the closing price for TOI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oncology Institute Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TOI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TOI

Analyst Price Target is $2.50
▲ +1,288.89% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Oncology Institute in the last 3 months. The average price target is $2.50, with a high forecast of $2.50 and a low forecast of $2.50. The average price target represents a 1,288.89% upside from the last price of $0.18.

This chart shows the closing price for TOI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Oncology Institute.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/26/2024Jefferies Financial GroupInitiated CoverageBuy$2.50
6/16/2023GuggenheimLower Target$3.00 ➝ $2.00
3/20/2023GuggenheimLower Target$6.00 ➝ $3.00
11/11/2022GuggenheimLower TargetBuy$7.00 ➝ $6.00
9/14/2022GuggenheimInitiated CoverageBuy$7.00
8/15/2022Jefferies Financial GroupInitiated CoverageBuy$10.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

-0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
Mentions as of
4/21/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 12 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/20/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 15 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 6 very negative mentions
Mentions as of
9/18/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
Mentions as of
10/18/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 5 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Oncology Institute logo
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Read More

Today's Range

Now: $0.18
Low: $0.18
High: $0.23

50 Day Range

MA: $0.30
Low: $0.18
High: $0.37

52 Week Range

Now: $0.18
Low: $0.18
High: $2.50

Volume

2,099,660 shs

Average Volume

199,405 shs

Market Capitalization

$13.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncology Institute?

The following sell-side analysts have issued research reports on Oncology Institute in the last twelve months: Jefferies Financial Group Inc..
View the latest analyst ratings for TOI.

What is the current price target for Oncology Institute?

0 Wall Street analysts have set twelve-month price targets for Oncology Institute in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 1,288.9%. Jefferies Financial Group Inc. has the highest price target set, predicting TOI will reach $2.50 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $2.50 for Oncology Institute in the next year.
View the latest price targets for TOI.

What is the current consensus analyst rating for Oncology Institute?

Oncology Institute currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TOI will outperform the market and that investors should add to their positions of Oncology Institute.
View the latest ratings for TOI.

What other companies compete with Oncology Institute?

Other companies that are similar to Oncology Institute include Enzo Biochem, Exagen, Burning Rock Biotech, Concord Medical Services and Renalytix. Learn More about companies similar to Oncology Institute.

How do I contact Oncology Institute's investor relations team?

Oncology Institute's physical mailing address is 345 PARK AVENUE SOUTH, NEW YORK NY, 10010. The company's listed phone number is 562-735-3226 and its investor relations email address is [email protected]. The official website for Oncology Institute is theoncologyinstitute.com. Learn More about contacing Oncology Institute investor relations.